MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10147-020-01721-x

Медицинская библиотека · International journal of clinical oncology · 2020

Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).

Okano Naohiro, Morizane Chigusa, Nomura Shogo, Takahashi Hideaki, Tsumura Hidetaka, Satake Hironaga, Mizuno Nobumasa, Tsuji Kunihiro, Shioji Kazuhiko, Asagi Akinori, Yasui Kohichiroh, Kitagawa Sho, Kashiwada Tomomi, Ishiguro Atsushi, Kanai Masashi, Ueno Makoto, Ogura Takashi, Shimizu Satoshi, Tobimatsu Kazutoshi, Motoya Masayo, Nakashima Koji, Ikeda Masafumi, Okusaka Takuji, Furuse Junji

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

A family/personal history of breast, ovarian, or pancreatic cancer is a useful predictive marker for response to platinum-based chemotherapy in treating patients with pancreatic cancer. These cancers, and prostate cancer, are known as BRCA-related malignancies. We evaluated the efficacy of gemcitabine plus oxaliplatin (GEMOX) in patients with metastatic pancreatic cancer with a family/personal history of these cancers.

METHODS

Chemotherapy-naïve patients with metastatic pancreatic cancer with a family history of pancreatic/breast/ovarian/prostate cancer or a personal history of breast/ovarian/prostate cancer were included. Patients received fixed dose-rate gemcitabine (1000 mg/m2) and oxaliplatin (100 mg/m2) every 2 weeks. The primary endpoint was 1-year survival, and the threshold and expected values were set at 30 and 50%, respectively. The target sample size was determined to be 43, with a one-sided alpha value of 5% and power of 80%. A total of 45 patients were enrolled.

RESULTS

Among the first 43 enrolled patients, the 1-year survival rate was 27.9% [90% confidence interval (CI) 17.0-41.3], which did not meet the primary endpoint. Median overall survival, progression-free survival, and response rates were 7.6 months (95% CI 6.0-10.7), 4.0 months (95% CI 2.0-4.6), and 26.7% (95% CI 14.6-41.9), respectively, in all registered patients. The GEMOX regimen was generally tolerated; the most common grade three or higher adverse events were hematological toxicities.

CONCLUSION

GEMOX did not show the expected efficacy in patients with metastatic pancreatic cancer with a family or personal history of pancreatic/breast/ovarian/prostate cancer. Selection of GEMOX based on family/personal history is not recommended.

TRIAL REGISTRATION NUMBER: UMIN000017894.

Для цитирования: Okano Naohiro, Morizane Chigusa, Nomura Shogo, Takahashi Hideaki, Tsumura Hidetaka, Satake Hironaga, Mizuno Nobumasa, Tsuji Kunihiro, Shioji Kazuhiko, Asagi Akinori, Yasui Kohichiroh, Kitagawa Sho, Kashiwada Tomomi, Ishiguro Atsushi, Kanai Masashi, Ueno Makoto, Ogura Takashi, Shimizu Satoshi, Tobimatsu Kazutoshi, Motoya Masayo, Nakashima Koji, Ikeda Masafumi, Okusaka Takuji, Furuse Junji. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).. International journal of clinical oncology. 2020. DOI: 10.1007/s10147-020-01721-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.